一、文章
1. Junpeng Fan; Yu Fu; Wenju Peng; Xiong Li; Yuanming Shen;Ensong Guo;Funian Lu; Shengtao Zhou;Si Liu;Bin Yang;Xu Qin; Dianxing Hu;Rourou Xiao;Xi Li;Siqi Yang; Cunzhong Yuan; Yao Shu;He Huang;Ting Wan;Yanan Pi;Shuxiang Wang;Wenjuan Chen;Haixia Wang;Lin Zhong;Yuan;Baogang Wen;Beihua Kong;Gordon B. Mills;Dongling Zou;* Bairong Xia;* Kun Song;* Gang Chen;* Ding Ma;* ;Chaoyang Sun. Multi-omics characterization of silent and productive HPV integration in cervical cancer. Cell Genom. 2023 Jan 11;3(1):100211.
2. Ling Wang; Xin Wang; Xueping Zhu; Lin Zhong; Qingxiu Jiang; Ya Wang; Qin Tang; Qiaoling Li; Cong Zhang; Haixia Wang; Dongling Zou*. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024 Mar 28;23(1):66
3. Mingfang Guo, Misi He, Yun Dang, Li Lei, Qiaoling Li, Yue Huang, Liang Du, Haike Lei, Qian Zheng 2, Jing Wang, Xiuying Li, Hao He, Xiang Zhang, Ying Tang, Qi Zhou, Dongling Zou*. Predictors of para-aortic lymph node metastasis based on pathological diagnosis via surgical staging in patients with locally advanced cervical cancer: A multicenter study. Cancer Lett. 2025 Apr 28;616:217545.
4. Qian Zheng, Di Shao , Jin Shu, Qin Zhang, Min Huang, Dong Wang, Dongling Zou*. The impact of integrated genomic analysis on molecular classifications and prognostic risk stratification in endometrial cancer: a Chinese experience. Front Oncol. 2025 Feb 6;15:1541 562.
5.Tian Chu#; Yifan Meng#; Ping Wu#; Zheng Li#; Hao Wen#; Fang Ren#; Dongling Zou#; Huaiwu Lu#; Lingying Wu#; Shengtao Zhou#; Ying Chen#; Jundong Li; Miaochun Xu; Xiaoliu Wu; Xi Xiong; Zhibin Wang; Misi He; Yuanyuan Zhang; Shitong Lin; Canhui Cao; Wencheng Ding; Yu Chen; Wenhua Zhi; Ting Peng; Ye Wei; Binghan Liu; Yashi Xu; Ding Ma; Jing Wang; Chaoyang Sun; Peng Wu ; The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry, The Lancet Oncology , 2023, 24(6): 701-708
6.Qin Tang; Xin Wang ; Haixia Wang;Lin Zhong;Dongling Zou*.Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer. Cancer Biol Med,2023,20(12):915-921.
7. Yi Wang; Misi He; Tiancong He; Xueyan Ouyang;Xuxia Shen; Wanling Shi; Shengling Huang ;Libing Xiang; Dongling Zou*;Wei Jiang; Huijuan Yang. Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers. British Journal of Cancer.2024.
8. Misi He;* Mingfang Guo;* Qi Zhou; Ying Tang;Lin Zhong; Qing Liu;Xiaomei Fan;Xiwa Zhao; Xiang Zhang; Gang Chen; Yuanming Shen; Qin Xu;Xiaojun Chen; Yuancheng Li; Dongling Zou*.Efficacy of lymph node dissection on stage IIICr of cervical cancer beforeCCRT: study protocol for a phase III, randomized controlled clinical trial(CQGOG0103). J Gynecol Oncol. 2023 May;34(3):e55
9. Tian Chu#, Yifan Meng#, Ping Wu#, Zheng Li#, Hao Wen#, Fang Ren#, Dongling Zou#, Huaiwu Lu, Lingying Wu, Shengtao Zhou, Ying Chen, Jundong Li, Miaochun Xu, Xiaoliu Wu, Xi Xiong, Zhibin Wang, Misi He, Yuanyuan Zhang, Shitong Lin , Canhui Cao, Wencheng Ding, Yu Chen, Wenhua Zhi, Ting Peng, Ye Wei, Binghan Liu, Yashi Xu, Ding Ma, Jing Wang, Chaoyang Sun, Peng Wu. The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry. Lancet Oncol. 2023 Jun;24(6):701-708. (IF =51.1).
10. Ning Li, Jianqing Zhu, Rutie Yin, Jing Wang, Lingya Pan, Beihua Kong, Hong Zheng, Jihong Liu, Xiaohua Wu, Li Wang, Yi Huang, Ke Wang, Dongling Zou, Hongqin Zhao, Chunyan Wang, Weiguo Lu, An Lin, Ge Lou, Guiling Li, Pengpeng Qu, Hongying Yang, Yu Zhang, Hongbing Cai, Yueyin Pan, Min Hao, Ziling Liu, Heng Cui, Yingjie Yang, Shuzhong Yao, Xiaoa Zhen, Wenzhao Hang, Jianmei Hou, Juan Wang, Lingying Wu. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023 Jul 13;e232283.
11. Xueju Wei #3, Yue Huo #, Jingnan Pi #, Yufeng Gao #, Shuan Rao # , Manman He #, Qinglv Wei, Peng Song, Yiying Chen, Dongxu Lu, Wei Song, Junbo Liang, Lingjie Xu 6, Haixia Wang, Guolin Hong, Yuehong Guo, Yanmin Si, Jiayue Xu, Xiaoshuang Wang, Yanni Ma , Shuyang Yu, Dongling Zou, Jing Jin, Fang Wang, Jia Yu. METTL3 preferentially enhances non-m6A translation of epigenetic factors and promotes tumourigenesis. Nat Cell Biol. 2022 Aug;24(8):1278-1290.
12. Long, Xingtao, Zhou, Qi; Zou, Dongling; Wang, Dong,Liu, Jingshu, Chen, Yuemei. Validation of the prognostic value of the 2018 FIGO stage IIIC in patients with cervical cancer. Gynecologic Oncology, 2021, 162.
13.Ding Dongyan#, Lang Tingyuan#*, Zou,Dongling, Tan Jiawei, Chen Jia, Zhou Lei, Wang Dong, Li Rong, Li Yunzhe, Liu Jingshu, Ma Cui, Zhou Qi*. Machine learning-based prediction of survival prognosis in cervical cancer. BMC bioinformatics, 2021,22(1):331.
14. Zou Dongling,Guo Mingfang, Zhou Qi*. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer. BMC cancer, 2021,21(1):661.
15.Wang Haixia, Shu Jin, Zou Dongling*; Zhou Qi*. Preliminary results of niraparib and brivanib dual therapy evaluation in recurrent, metastatic and persistent cervical cancer (CQGOG0101): An open-label, phase II clinical trial. Journal of Clinical Oncology, 2021, 39(15_suppl):e17506- e17506.
16. Zou Dongling, Li Zirong, Liu Jing, Gao Yunong, Zheng Hong, Yuan Mingming, Wang Haixia, Yuan Li,Wang Dong, Liu Jingshu,Chen Rongrong, Xia Xuefeng, Zhou Qi. Association of alterations in DNA damage repair and Notch pathways with high tumor mutational burden in patients with cervical cancer. Journal of Clinical Oncology, 2021, 39(15_suppl): e17511-e17511.
17．Liu Jingshu, Qiu Jiangfeng, Zhang Zhiqi, Zhou Lei, Li Yunzhe, Ding Dongyan, Zhang Yang, Zou, Dongling, Wang Dong, Zhou Qi*, Lang Tingyuan*. SOX4 maintains the stemness of cancer cells via transcriptionally enhancing HDAC1 revealed by comparative proteomics study. Cell & bioscience, 2021,11(1):23.
18. Liu, Tao#; Wei, Qinglv#; Jin, Jing#; Luo, Qingya; Liu, Yi; Yang, Yu Cheng, Chunming; Li, Lanfang; Pi, Jingnan; Si, Yanmin; Xiao, Hualiang; Li, Li; Rao, Shuan; Wang, Fang; Yu, Jianhua; Yu, Jia*; Zou, Dongling*; Yi, Ping*; The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. , Nucleic Acids Research, 2020, 17(48): 3816-3831 (IF =11.147).
19. Zou, Dongling*; Dong, Lei; Li, Chenying; Yin, Zhe; Rao, Shuan*; Zhou, Qi*; The m(6)A eraser FTO facilitates proliferation and migration of human cervical cancer cells , Cancer Cell International, 2019, 19(321)(IF=3.439).
20.Su Rui#; Dong Lei#; Li Chenying#; Nachtergaele Sigrid#; Wunderlich Mark;Qing Ying; Deng Xiaolan; Wang Yungui; Weng Xiaocheng; Hu Chao; Yu Mengxia;Skibbe Jennifer; Dai Qing; Zou Dongling; Wu Tong; Yu Kangkang; Weng Hengyou;Huang Huilin; Ferchen Kyle; Qin Xi; Zhang Bin; Qi Jun; Sasaki Atsuo T; Plas David R; Bradner James E; Wei Minjie; Marcucci Guido; Jiang Xi; Mulloy James C;Jin Jie*; He Chuan*; Chen Jianjun*; R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/ CEBPA Signaling , Cell, 2018, 172(1-2): 1-16(IF=36.216).
21.Zhang, Zhengyi#; Pi, Jingnan#; Zou, Dongling#; Wang, Xiaoshuang#; Xu,Jiayue; Yu, Shan; Zhang, Ting; Li, Feng; Zhang, Xianxie; Zhao, Hualu; Wang,Fang; Wang, Dong*; Ma, Yanni*; Yu, Jia*; microRNA arm-imbalance in part from complementary targets mediated decay promotes gastric cancer progression , Nature Communications, 2019, 10(4397): 1-16(IF=11.878).
22. Zou Dongling; Zhou Qi; Wang Dong; Guan Lili; Yuan Li; Li Shaolin*; The Downregulation of MicroRNA-10b and its Role in Cervical Cancer , Oncology Research, 2016, 24(2): 99-108 (IF= 4.634).
23. Dongling Zou；Dong Wang； Rong Li；Ying Tang；Li Yuan； Xingtao Long；Qi Zhou*；MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK；Tumor Biology, 2015, 36(9): 6725-6732.DOI: 10.1007/s13277-015- 3365-7 (IF= 1.727).
24．Jia Hongyan#; Zhang Zhengyi#,Zou Dongling#; Wang Bin#; Yan Yunmeng; Luo Min; Dong Lei; Yin Haixin; Gong Bei; Li Zheng; Wang Fang; Jia Yu*；MicroRNA-10a Is Down-Regulated by DNA Methylation and Functions as a Tumor Suppressor in Gastric Cancer Cells，PLos One，2014,9（1）：e88057，DOI:10.1371/journal. pone. 0088057(IF=2.776).
25．Lei Huizi#,Zou Dongling#; Li Zheng#; Luo Min; Dong Lei; Wang Bin; Yin Haixin; Ma Yanni; Liu Changzheng; Wang Fang; Zhang Junwu; Yu Jia*; Li Yu*；MicroRNA-219-2-3p Functions as a Tumor Suppressor in Gastric Cancer and Is Regulated by DNA Methylation；PLos One, 2013, 8(4): e60369. DOI:10.1371 /journal . pone. 0060369(IF=2.776).
26. Lihua Guo#; Hua Bai#; Dongling Zou#; Tao Hong; Jie Liu; Jiaqiang Huang; Pengfei He; Qi Zhou*; Jinsheng He*；The role of microRNA-133b and its target gene FSCN1 in gastric cancer Journal of Experimental & Clinical Cancer Research, 2014, 33(1): 99.DOI:10.1186/preaccept-1248701577135074(IF=5.646).
27. Mingfang Guo#; Misi He#;Qi Zhou#;Dongling Zou#; Predictors of para-aortic lymph node metastasis based on pathological diagnosis via surgical staging in patients with locally advanced cervical cancer: A multicenter study. Cancer Lett.
28. Hongji Wu#;Lifang Ma#,Zou Dongling#;Haixia Wang#;Development and validation of deep learning for predicting the growth of ovarian cancer organoids. Chin Med J (Engl)
29. Li Yuan#; Haike Lei #; Dongling Zou#; Qi Zhou#; A Chinese prospective cohort research developed and validated a risk prediction model for patients with cervical cancer. Cancer Cell Int.
30. Qian Zheng#; Misi He#; Dongling Zou#; Advancing the Fight Against Cervical Cancer: The Promise of Therapeutic HPV Vaccines. Vaccines (Basel).
31. Haixia Wang#;Dongling Zou#;Qi Zhou#;Multicenter study of ovarian cancer score for diagnosing ovarian cancer. Gynecol Oncol.
32. Xiujuan Zhao#;Qi Zhou#;Dongling Zou#; Dosimetric and clinical outcomes study of occult uterine tandem imperfect implantation in HDR-brachytherapy for cervical cancer. Sci Rep.
33. Jiaze Mao#;Ling Long#;Dongling Zou #; Risk factors associated with overall survival in patients with cervical cancer: a prospective cohort study in Western China comparing random survival forest and Cox proportional hazards models. J Gynecol Oncol.
34. Qian Zheng#;Dong Wang #;Dongling Zou #;The impact of integrated genomic analysis on molecular classifications and prognostic risk stratification in endometrial cancer: a Chinese experience. Front Oncol.
35. Haixia Wang#;Ling Wang#;Xueping Zhu#;Misi He#;Dongling Zou #;Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer. J Transl Med.
二、专利
1. 发明专利；一种妇科护理清洗器；CN114191635B；邹冬玲；中国
2. 发明专利；宫颈癌细胞三维培养装置及其应用；CN110157617B；吴科，张勤，陈文娟，王冬，邹冬玲；中国
3. 发明专利；一种检测ISYNA1表达水平的试剂在制备卵巢癌干性鉴别试剂中的应用；CN114752673B；杨玲玲，郎廷元，周琦，杨牧垚，崔晨曦，邹冬玲；中国
4. 发明专利; 一种检测AHCTF1表达水平的试剂在制备判断卵巢癌干性程度的试剂中的应用；CN114686590B；崔晨曦，郎廷元，周琦，杨牧垚，杨玲玲，邹冬玲；中国
5. 发明专利：一种宫颈癌类器官培养基及其应用；CN 116555165 B；邹冬玲;何密斯;王海霞;朱雪萍;郑倩;隆玲;毛泽佳；中国
6. 发明专利：一种类器官生长预测方法、系统及设备；CN116129193B；邹冬玲;王海霞;何密斯;朱雪萍;吴洪基；中国
7. 发明专利：一种宫颈癌类器官的构建方法及应用；CN 116716236 B；邹冬玲，何密斯，王海霞，朱雪萍，郑倩，隆玲，毛泽佳 ; 中国
8. 实用新型专利：一种自动化的类器官液体分装系统；CN 219603592 U；梁俊波，刘长征，宋伟，余佳，邹冬玲；中国
9. 实用新型专利：一种有效进行类器官处理及分析的自动化系统；CN 219603578 U；余佳，宋伟，刘长征，梁俊波，邹冬玲；中国
三、承担和参与的科学研究项目
[1]评价Datopotamab Deruxtecan（Dato-DXd）单药和与抗癌药物联合治疗晚期/转移性实体瘤患者有效性和安全性的II期、多中心、开放性研究（TROPION-PanTumor03），2023.04，国内多中心，在研。
[2]一项在晚期/转移性实体瘤研究参与者中评价Volrustomig单药治疗或与抗肿瘤药物联合治疗的有效性和安全性的多中心、II期临床研究主方案-研究子宫颈癌，2024.02，国内多中心，在研。
[3]评价洛奈利单抗联合含铂化疗±贝伐珠单抗一线治疗晚期、持续、复发/转移性宫颈癌患者的有效性和安全性的多中心、随机、双盲、安慰剂对照的Ⅱ/Ⅲ期临床研究，2024.08，国内多中心，在研
[4]一项Volrustomig治疗含铂类同步放化疗后未进展的高风险局部晚期宫颈癌女性的随机、双盲、安慰剂对照、多中心、全球III期研究（eVOLVE-Cervical），2025.02，全球多中心，在研（牵头人）。
[5]注射用HS-20124在晚期实体瘤受试者中的安全性、耐受性、药代动力学和有效性的I期临床研究，2025.03，国内多中心，在研。
[6]评估JSKN033在晚期恶性肿瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的 I/II 期临床研究，2025.01，国内多中心，在研
[7]西奥罗尼联合紫杉醇周疗治疗铂难治或铂耐药复发卵巢癌患者的随机、双盲、对照、多中心III期临床试验，2022.05，国内多中心，在研。
[8]GC203 TIL细胞注射液治疗晚期恶性实体瘤患者的开放标签、单臂、I期临床试验（KUNLUN-001），2024.04，国内多中心，在研。
[9]一项评价注射用 HS-20089 对比研究者选择的化疗用于治疗铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌的多中心、随机、开放、对照、Ⅲ期临床研究，2025.05，国内多中心，在研。
[10] 一项评价QLS5132单药用于治疗晚期实体瘤受试者的临床研究，2025.10，国内多中心，在研。
[11] 在铂耐药复发上皮性卵巢癌患者中对比BL-B01D1与医生选择的化疗的III期随机对照临床研究，2025.09，国内多中心，在研。
[12] 注射用KH815在晚期实体瘤患者中的I期临床研究，2025.08，国内多中心，在研。
[13] 注射用HS-20124在晚期实体瘤受试者中的I期临床研究，2025.04，国内多中心，在研
[14] 评估IBI363联合贝伐珠单抗治疗晚期实体瘤受试者的有效性和安全性的II期临床研究，2025.09，国内多中心，在研。
[15] 淋巴结切除对宫颈癌IIICr期疗效影响的随机对照试验（NCT04555226），2020.09，自主发起的临床研究，已完成clinical trails注册，在研（牵头）
[16] 对比前哨淋巴结活检与系统性淋巴结清扫对术前局限于子宫的子宫内膜癌预后影响的非劣效随机对照试验，2021.04，自主发起的临床研究，已完成clinical trails注册，在研。
[17] 早期上皮性卵巢癌免于系统淋巴结切除的多中心随机对照研究，2020.10，自主发起的临床研究，已完成clinical trails注册，已完成。
[18] 局部晚期宫颈癌手术分期对比影像分期的非随机同期对照临床研究，2022.06，自主发起的临床研究，已完成clinical trails注册，在研（牵头）。
[19] 辅助化疗在局部晚期宫颈癌同步放化疗后残留病灶患者中疗效的随机对照试验，2022.07，自主发起的临床研究，已完成clinical trails注册，在研。
[20] 氟唑帕利联合贝伐珠单抗用于PARPi经治铂敏感复发卵巢癌的前瞻性、单臂、多中心的Ⅱ期临床研究，2022.08，自主发起的临床研究，已完成clinical trails注册，在研（牵头）。
[21] 挽救性手术在局部晚期宫颈癌同步放化疗后残留肿瘤患者中疗效的单臂研究，2022.07，自主发起的临床研究，已完成clinical trails注册，在研。
[22] 腹主动脉旁淋巴结转移预测模型在局部晚期宫颈癌中的应用及对预后影响的前瞻性研究，2023.02，自主发起的临床研究，已完成clinical trails注册，在研。
[23] 肿瘤放疗后B细胞恢复障碍的临床研究自主发起的临床研究，2024.04，已完成clinical trails注册，已完成。
[24] 恩朗苏拜单抗序贯同步放化疗治疗局部晚期宫颈癌的单臂探索性研究，2024.11，自主发起的临床研究，已完成clinical trails注册，在研。
[25] 根治性手术后联合或不联合辅助治疗在中风险早期宫颈癌患者中疗效对比的一项国际多中心随机对照试验（NCT04989647），2025.04，国际多中心，在研。
[26] 智能仿生类器官芯片技术研究，2025 年智慧医疗装备与前沿技术专项重点项目，在研。
[27] 肿瘤类器官高通量药物筛选关键技术的研究与应用，2025重庆市科卫联合医学科研重大项目，在研。
[28]
四、相关奖励与荣誉
[1] 2023.8，重庆市卫生健康系统先进个人
[2]2023.3，重庆市三八红旗手
[3]2020.4，重庆市科技局科技进步二等奖，第二完成人；
[4]2020.4，中国抗癌协会科技二等奖，第二完成人；
[5]2019.11,亚洲妇科肿瘤协会(ASGO)优秀青年医师（中国共2人）;
[6]2015.6，国家共青团中央“最美青工”；
[7]2014.6，中华肿瘤明日之星；
[8]2013.6，中华肿瘤明日之星。
